Results: Thirteen of the 15 patients who developed a malignancy and all 5 of the patients who developed HLH had been exposed to thiopurine; 10 patients with malignancy patients had also been exposed to a biologic agent. Unadjusted incidence rates showed no increased risk of malignancy (0.46/1000 patient-years) or HLH (0.0/1000 patient-years) in patients exposed to infliximab as the only biologic vs those unexposed to biologics (malignancy: 1.12/1000 patientyears; HLH: 0.56/1000 patient-years). SIRs did not demonstrate an increased risk of malignancy among patients exposed to infliximab (SIR; 1.69; 95% CI, 0.46-4.32) vs patients not exposed to a biologic agent (SIR, 2.17; 95% CI, 0.59-5.56), even when patients were stratified by thiopurine exposure.
Conclusions:
In determination of age-, sex-and race-adjusted SIRs using data from a large clinical trial and the SEER database, we found that infliximab exposure did not associate with 
Introduction
Crohn's disease (CD) and ulcerative colitis (UC), which comprise inflammatory bowel disease (IBD), are characterized by chronic inflammation of the gastrointestinal tract. Nearly 25% of cases are diagnosed during childhood, and the incidence of IBD is increasing in children. 1, 2 The associations between IBD and intestinal malignancies, including colorectal carcinoma, small bowel adenocarcinoma, and intestinal lymphoma are well established; extraintestinal malignancies related to IBD include lymphoma, leukemia, and skin cancers. 3, 4 Risk factors for malignancy associated with IBD include local and systemic inflammation leading to immune dysregulation with impaired tumor surveillance; 5 the carcinogenic effects of immunosuppressive therapy, particularly with respect to extra-intestinal malignancies; 6 as well as exposure to environmental factors including ionizing radiation. 7 Assessment of the comparative effects of different therapies upon malignancy risk in IBD is complicated by multiple factors including confounding by indication. Patients with more severe disease may have an increased risk of malignancy due to ongoing inflammation, but due to disease severity are also more likely to receive certain medications, including immunomodulators and biologic agents, such anti-tumor necrosis factor-alpha (anti-TNF-α) therapies. 8 Furthermore, serial, combination, and intermittent treatment involving thiopurines (6-mercaptopurine and azathioprine), the most widely used immunomodulator agents in IBD, and anti-TNF-α therapies may have additive or synergistic risks. The relative impact of duration of exposure versus cumulative dose of thiopurines and anti-TNF-α therapies is not well characterized. 9 Recent studies suggest that in patients with IBD who discontinue thiopurines, M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 12 the risk of lymphoma may decrease to the risk in patients with IBD never exposed to thiopurines; however, it is not clear when this risk potentially diminishes. [10] [11] [12] Although not considered a true malignancy, but rather a disorder of immune hyperstimulation and dysregulation, hemophagocytic lymphohistiocytosis (HLH) is also associated with IBD and may have catastrophic consequences, including death. Similar to IBD-associated malignant lymphoproliferative disorders, such as lymphoma, the risk of HLH in patients with IBD is increased in the setting of systemic inflammation and exposure to immunosuppressive therapy, particularly thiopurines, with concurrent primary infection with Epstein-Barr virus (EBV). 13 Prior reports on the risk of malignancy and HLH associated with therapy for pediatric patients with IBD have been limited to largely retrospective studies with small sample sizes and/or limited duration of follow-up (F/U), systematic reviews of data pooled across multiple studies, or case series. [13] [14] [15] [16] Utilizing data from the DEVELOP Registry (An Inflammatory Bowel Disease Multicenter, Prospective, Long-term Registry of Pediatric Patients, NCT00606346), the objectives of this study in pediatric patients with IBD were (1) to compare unadjusted incidence rates of malignancy and HLH in infliximab (IFX)-exposed patients vs. those unexposed to biologics and (2) to calculate standardized incidence ratios (SIRs) with 95% CIs using the Surveillance, Epidemiology, and End Results (SEER) database, in order to compare the incidence of malignancy in pediatric patients with IBD exposed to infliximab vs. those unexposed to biologics.
Methods

Study design
DEVELOP is a multicenter, prospective, cohort study of long-term safety and clinical outcomes in pediatric patients with CD, UC or IBD-unclassified (IBD-U) treated with REMICADE ® (infliximab) and/or other medical therapies for IBD. Enrollment commenced in 2007 and is currently ongoing, and patients are to be followed for 20 years (see Figure 1 for study design). 
As
Study participants/evaluations
Eligible participants included pediatric patients with a confirmed diagnosis of IBD (i.e., CD or UC or IBD-U) for at least 2 months, and at the time of enrollment were less than 17 years of age in North America, and 6 years to less than 17 years of age in the EU. Patients were ineligible to participate in the study if they had a history of other IBD-like conditions associated with genetic diseases (i.e. glycogen storage disease 1b), were participating in any clinical trial for an investigational agent that was not commercially available, or were currently participating in another study supported by the sponsor.
Patient data were collected at enrollment and then approximately every six months. history were collected at F/U visits. All malignancy and HLH cases were validated with supporting documentation, including pathology reports.
Statistical analysis
Medication exposure was defined as "ever-exposed," which includes exposure at any time prior to the malignancy or HLH event. The study population was divided into the following cohorts: infliximab (exposure to infliximab as the only biologic in the presence or absence of exposure to non-biologics), biologics (exposure to any biologic, including infliximab, in the presence or absence of exposure to non-biologics), and non-biologics (exposure to 5aminosalicylates, corticosteroids, thiopurines, methotrexate, antibiotics, or other non-biologic IBD therapies, in the absence of exposure to any biologics). The infliximab cohort is a subgroup of the biologics cohort, which includes exposure to anti-TNF-α and/or non-anti-TNF-α biologics.
Each of these cohorts was further stratified by thiopurine and methotrexate exposure. At baseline, patients were included in a treatment cohort based on cumulative medication exposure at the time of study enrollment. Given this is a long-term study in which study participants may have had changes in medication regimens, total patient-years of exposure for a single participant may include contributions to more than one cohort, and a malignancy or HLH event was assigned to a specific cohort based on cumulative exposure at the time of the event. For example, a patient exposed to 1 year of non-biologic immunomodulator therapy in the absence of biologics followed by 2 years of infliximab therapy (either in the presence or absence of an immunomodulator) at the onset of a malignancy or HLH event would have Baseline demographic and disease characteristics were evaluated for the entire study population as well as by exposure cohort using descriptive statistics, i.e., means and standard deviations for continuous variables and frequencies and percentages for categorical outcomes.
For the comparisons among the infliximab, biologics, and non-biologics cohorts, the Wilcoxon rank sum test was used for continuous variables and Chi-square test was used for categorical variables. The rates of malignancy events per 1000 patient-years of follow-up were calculated for each medication exposure cohort as the quotient of the total number of malignancy events and cumulative patient-years of exposure, then multiplied by 1000, and expressed with a corresponding 95% CI. The incidence rates of malignancy events for each exposure cohort, as well as for the entire study population, were also stratified by thiopurine exposure; similar analyses were performed using stratification by methotrexate exposure. The incidence of HLH was calculated for the entire study population and then stratified by thiopurine and methotrexate exposure. Standardized incidence ratios (SIRs) with 95% CI using the SEER program database 20 were also used to compare the incidence rates for malignancy. SIRs were calculated as the quotient of the observed number of malignancy events in an exposure cohort
and the expected number of malignancy events in the general US pediatric population in the SEER database, with adjustments for age, gender, and race. A SIR with the lower bound of 95% CI greater than 1.0 indicates a statistically significantly increased risk for the development of malignancy, compared to the SEER reference population. Similar to the unadjusted analyses, SIRs were also calculated stratified by thiopurine and methotrexate exposure. Of note, the SEER database does not include non-melanoma skin cancers (NMSC). As such, the 2 cases of basal cell carcinoma reported in this study were excluded from the SIR analyses. Statistical comparisons between the infliximab and biologics cohorts and the respective non-biologics cohorts as well as the entire study population stratified by thiopurine exposure were made by calculation of the ratio of the SIRs with 95% confidence intervals; a confidence interval including 1.0 indicated no statistically significant differences between SIRs. Data were analyzed using SAS software version 9.2 (SAS Institute, Cary, NC).
Results
Patient characteristics and treatment
Baseline patient characteristics are summarized in Table 1 (p<0.005, both). The biologics cohort (n=2824) predominantly was comprised of patients with anti-TNF-α biologic exposure, including: infliximab (94.6%), adalimumab (34.0%), certolizumab (5.1%), golimumab (0.6%), and etanercept (0.2%); note that these categories are not mutually exclusive as patients may have received more than one anti-TNF-α therapy. A total of 232 patients in the biologics cohort were exposed to non-anti-TNF-α biologic agents for a total of 404.2 patient-years; 15 of these patients were exposed to non-anti-TNF-α biologic agents in the absence of TNF-α biologic agents. Specific exposures for the 232 patients exposed to non-anti-TNF-α therapies included the following: vedolizumab (78.9%), ustekinumab (18.1%), and natalizumab (9.1%), with 15.5% of patients exposed to at least one other non-anti-TNF-α biologic therapy; these categories are not mutually exclusive as patients may have been exposed to more than one non anti-TNF-α biologic agent. (1), and mycosis fungoides (1). Ten patients were exposed to infliximab, and among them, five patients were also exposed to adalimumab; 6 patients were exposed to methotrexate; and nine of ten infliximab-exposed patients were also exposed to thiopurines. Four patients were exposed to thiopurines in the absence of biologics. Thus, 13 of the 15 patients with malignancies were exposed to thiopurines; and the majority of these
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patients developed malignancy after less than 5 years of thiopurine exposure. Specific therapies at the time of malignancy diagnosis are detailed in renal cell carcinoma were alive as of the data cut-off. increased risk for both of these events in thiopurine-exposed patients. Similar findings were observed for the biologics cohorts versus the non-biologics cohorts for all of the above unadjusted analyses, including analyses stratified by thiopurine exposure. biologic plus thiopurine exposed compared to the SEER reference population. Patients exposed to non-biologics, stratified by thiopurine exposure, had no evidence of increased risk of malignancy compared to the SEER reference population. Panel B indicates that stratification of the entire study population by thiopurine exposure demonstrated a statistically significantly increased malignancy risk in patients exposed to thiopurines compared to SEER database, with or without biologic exposure. The ratio of the SIRs for the thiopurine-exposed patients compared with thiopurine non-exposed patients indicated no statistically significant difference.
Incidence of Malignancy and HLH
Additionally, SIRs without stratification by thiopurine exposure (Supplemental Table 3 ), indicated no increased risk of malignancy in the infliximab or the biologics cohorts versus the non-biologics cohort.
In comparison to the number of patients exposed to thiopurines, far fewer were exposed to methotrexate; 3857 patients had 17224.1 patient-years of exposure to thiopurines, and 1509 patients were exposed to methotrexate with 5710.0 patient-years of follow-up. Of the 1509 methotrexate-exposed patients, 977 also had exposure to thiopurines, with only 532 exposed only to methotrexate in the absence of thiopurines for a duration of 1630.1 patientyears. Comparison of unadjusted incidence rates of malignancy by exposure cohorts, additionally stratified by methotrexate exposure demonstrated no increased rates in the methotrexate-exposed cohorts vs. the methotrexate-unexposed cohorts. Additionally, stratification of the entire study population by methotrexate exposure showed no increased incidence of malignancy, HLH, or both malignancy and HLH in the methotrexate-exposed cohort vs. the methotrexate-unexposed cohort. (Supplemental Table 2 )
Discussion
Clinicians caring for children with IBD face important challenges as they outline the benefits and risks of therapeutic alternatives for patients and families. Studies have shown the efficacy of anti-TNF-α agents in inducing and maintaining remission in pediatric Crohn's disease 21, 22 and ulcerative colitis, 23 as well as improved one year clinical outcomes, including growth and development, in children with new onset Crohn's disease following early anti-TNFα therapy. [24] [25] [26] Nonetheless, many families, as well as clinicians, remain reluctant to use anti-TNFα therapy secondary to the fear of malignancy until a patient has failed conventional nonbiologic therapies, including thiopurines. This "step up approach" often does not take into account the risks of disease progression due to suboptimal treatment. Missing from this deliberation are robust data on the risk of malignancy in pediatric patients with IBD exposed to the wide range of available therapies.
Data from DEVELOP, the largest prospective cohort study of long-term safety outcomes in pediatric patients with IBD to date, indicate that infliximab therapy is not associated with an increased risk of malignancy. Furthermore, the data demonstrate a trend toward an increased risk of malignancy in thiopurine-exposed patients, irrespective of biologic exposure. Prior (95% CI, 2.01-13.9) in patients with IBD exposed to thiopurines. Other studies have suggested that there is an increased risk of lymphoma in patients with IBD both on thiopurines alone and in combination with an anti-TNF-α agent. 28, 31, 32 In a systematic analysis, Dulai, et. al.
M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 23 demonstrated that among pediatric patients with IBD, the lymphoma risk was no greater in patients who received anti-TNF-α therapy compared to those treated with other therapies. 15 Multiple studies have demonstrated an association between thiopurines and NMSC risk in patients with IBD; 30 of note, one case of basal cell carcinoma in our study was exposed to thiopurines in the absence of biologics. Although consistent with prior reports, this is the first study in pediatric patients with IBD to include both infliximab-exposed and infliximab-and biologic-unexposed cohorts with significant patient years of F/U for the purposes of robust comparisons using the SEER database. Comparisons between infliximab monotherapy vs.
infliximab/thiopurine combination therapy were also possible, due to the extensive patientyears of follow-up for each cohort. The prospective nature of the study allowed for the collection of detailed medical history, including duration of medication exposure prior to and during study participation.
In our study, we also observed 5 cases of HLH, a potentially fatal lymphoproliferative disorder that more commonly occurs in immunocompromised individuals. Though not considered a true malignancy secondary to the lack of monoclonality of the proliferating cell population, the associations between EBV infection, thiopurine use, and lymphoma as well as non-malignant lymphoproliferative disorders such as HLH in adult and pediatric patients with IBD are well-established. 11, 13, 31, 33 Our study also highlights the role of thiopurines in the pathogenesis of HLH, as all five patients who developed HLH were exposed to thiopurines but not exposed to biologics or methotrexate. It is postulated that chronic lymphopenia due to of infected lymphocytes, with ensuing complications. 13 The Cancers Et Surrisque Associé aux Maladies inflamma toires intestinales En France (CESAME) study reported that over 52% of the 23 cases of lymphoproliferative disorders were EBV positive, 11 with an incidence rate of 0.1/1000 patient-years for primary EBV infection-related post-mononucleosis lymphomas, a phenomenon observed in EBV naïve young men less than 35 years of age. 34 Given EBV exposure does occur in the majority of individuals as children or young adults, the pediatric age group is particularly vulnerable to repercussions of primary infection. Although the cases of HLH reported in this study represent a related but different diagnostic and pathologic entity and are very rare, it should be noted that when limited to the primary EBV-associated cases, a higher incidence rate of 0.2/1000 patient-years compared to the CESAME rate of EBV-related post-mononucleosis lymphoma, was observed. Also different about the HLH cases reported here are three of the five patients who developed HLH were adolescent females and that one case of HLH was associated with CMV infection ( Table 3 ). As such, both male and female pediatric patients with IBD exposed to thiopurine therapy should be considered at risk for HLH, and viral infections such as EBV and CMV infection should be considered in the differential diagnosis or as potential triggers for disease when patients are diagnosed with HLH. Notably, given the infrequency of these cases, it has not been possible to compare incidence rates for HLH in pediatric patients with IBD by specific exposures prior to the conduct of this study.
A key limitation of the study is related to the fact that malignancy events in this patient population are rare. Based upon an event rate of .61/1000 patient-years (15 events/24543 patient-years), the study has the power to detect a 4.2 fold or higher risk between any pairwise categorization of this cohort (e.g., thiopurine-exposed vs thiopurine non-exposed,
A C C E P T E D ACCEPTED MANUSCRIPT 25 biologic-exposed vs biologic-non-exposed). As such, 65 events with 106,000 patient-years would be required to detect a 2 fold or higher difference. Due to this fact, the study was not able to demonstrate statistically significant differences in malignancy risk between cohorts in the entire population or individual cohorts stratified by thiopurine exposure. Immortal time bias may also have confounded our results, as there may not have been sufficient follow-up time for events to occur. Although the data demonstrate increased malignancy risk in patients exposed to biologics and thiopurines compared to the respective SEER reference populations, this observation may be due to confounding by indication; patients in the biologics cohort may have a higher likelihood of adverse events due to greater disease activity and may have been exposed to more than one biologic. Additionally, these patients may have had a longer duration of follow-up. Also, the analyses assume that patients in the SEER database do not have IBD or are not exposed to these classes of medications. If this assumption were not true, the results would be biased toward a relative risk of 1. An additional limitation of our study is that 3/15 patients with malignancy were from France, and the SEER reference population is entirely from the US; differences between the SEER reference population and that in the EU could be a potential source of bias. Other limitations of the study include the fact that although prospective in nature, due to the fact that patients were evaluated every 6 months in a noninterventional study versus a clinical trial during which they may have had more frequent visits, there may have been under-reporting of adverse events, including malignancy and HLH.
However, if there were under-reporting of adverse events, there is no evidence to suggest that it would have been differential across the cohorts. Loss to follow-up is also a limitation of longterm safety registries.; the attrition rate of 20.1% for the total study population, although M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 26 comparable to other registries, was relatively high compared to administrative databases. 27, 35 However, comparison of attrition rates across the different cohorts showed no significant differences (Table 1) . Additionally, despite the fact that consecutive patients at every site were offered participation in the study, there may have been selection bias, which could have potentially contributed to under-reporting of malignancy or HLH events. The study was not able to comment on the impact of different IBD therapies upon the risk of the development of hepatosplenic T-cell lymphoma, as no cases have been identified in our patient cohort as of the data cut-off. The six methotrexate-exposed patients who developed malignancy also had prior exposure to thiopurines and infliximab. Our data on the effect of methotrexate exposure on risk of malignancy are limited because of the relatively small numbers of patients exposed to methotrexate. Additional long term data from DEVELOP will more clearly define the potential malignancy risk potential of methotrexate therapy alone or in combination with anti-TNF-α agents. Finally, our study did not collect detailed data on ionizing radiation, which may be associated with increased malignancy risk. 36 Consequently, we cannot draw meaningful conclusions regarding the impact of this exposure.
Our findings may inform the decision-making process in constructing treatment plans for children with IBD and communicating risks of different therapies to patients and families. The SIRs presented in Figure 2 present the risk of malignancy (excluding NMSC) in different treatment cohorts, relative to the SEER reference population. Presentation of these data as incidence rates (events/10,000 patient-years) may provide clinicians with another format in which to present these risks, relative to the incidence rate of 2.2/10,000 patient-years in the general US pediatric population (Supplemental Table 4 ). Recent studies have suggested that cessation of thiopurines in patients with IBD may reduce lymphoma risk [10] [11] [12] M A N U S C R I P T In summary, this study demonstrates that pediatric patients with IBD exposed to biologics in combination with thiopurines or thiopurines in the presence or absence of biologics have significantly increased risks of malignancy, compared to the respective SEER reference populations. The analyses establish an association between thiopurine exposure and the development of malignancy, which previously has only been shown in adult studies or systematic reviews which have pooled data from multiple pediatric studies. Furthermore, this study provides additional evidence for the association between thiopurine exposure and HLH, for which there are even more limited data. Given the recent data in adults suggesting the minimal effect of thiopurines in changing the natural history of CD, 37, 38 An SIR with the lower bound of 95% CI < 1.0 indicates no evidence of increased risk for the development of malignancy, compared to the SEER reference population, adjusted for age, gender, and race. Comparisons between the infliximab and biologics cohorts and the respective non-biologics cohorts as well as the entire study population stratified by thiopurine exposure were made by examination of ratios of the SIRs and revealed no statistically significant differences. Additionally, the SEER database does not include non-melanoma skin cancers (i.e., basal cell carcinoma); therefore, the 2 cases of basal cell carcinoma were excluded from the SIR analyses. * "All patients" includes the entire study population, as well as the sum of thiopurine-exposed and thiopurine non-exposed patients, and the sum of the biologics ± thiopurines and non-biologics ± thiopurines cohorts. The infliximab ± thiopurines cohort is a subset of biologics ± thiopurines cohort. The biologics cohorts include primarily exposure to anti-TNF-α biologics; 137 patients were exposed to non-anti-TNF-α biologics, either with or without thiopurines for a total of 210.1 patient-years of exposure. TNF=Tumor necrosis factor Thiopurine exposed ± Biologics Thiopurine non-exposed ± Biologics All patients Table S5 . Standardized incidence ratios (SIR) for the development of malignancy using the Surveillance, Epidemiology, and End Results (SEER) database with thiopurine-exposed patients stratified by ongoing exposure at malignancy diagnosis All Patients Thiopurine-exposed Thiopurine non-exposed 
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